植耀輝: 恆指續窄幅上落 石藥(01093.HK)績佳可續留意
耀才證券研究部總監植耀輝稱,港股昨日(26日)繼續呈拉鋸格局,於25,500點水平爭持,大市焦點仍是一眾科技股,個別如京東(09618.HK)繼續創上市新高,相反物管及醫療股則續受壓。最終恆指微升5點,收報25,491點,成交金額1,332億元。
由於大市仍未有清晰方向,相信資金仍只會集中炒作科技相關股,同時新股認購反應熱烈,亦可能對市況有一定影響,預期短期將繼續於25,500點水平上落。
股份方面,昨日繼續有多間公司公布中期業績,當中石藥集團(01093.HK)表現不俗,股價上升近5%。雖然收入增幅只得12.6%,但主業成藥增長仍達16.7%,相比之下維生素C及抗生素收入則錄得跌幅。毛利率亦因創新藥業務佔比提升而由69.9%升至75%。股東應佔溢利則增加23.2%至23.14億元人民幣。值得一提的是,集團研發投入仍維持較高水平,期內研究費用達14.52億元人民幣,同比增加54.2%,約佔成藥業務收入14.2%。研發種類亦主要聚焦在腫瘤、自身免疫、精神神經、消化和代謝、心腦血管系統及抗感染治療領域上。
至於股價表現,由於業績表現理想,加上集團派發中期息之餘同時宣布五送三紅股,股價出現突破,基於現價計估值仍算合理,故可繼續作中線持有。
(筆者為證監會持牌人,持並未持有相關股份)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.